Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial
Explore this paper's citation graph
Summary
It is indicated that irinotecan is active and well tolerated in patients with metastatic gastric adenocarcinoma and warrants further evaluation in this clinical setting.
- Type
- article
- Published
- 2003-09-09
- Cited by
- 87
- References
- 29
- Access
- Open access
- OpenAlex
- https://openalex.org/W2012792853
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:8130831
Keywords
Irinotecan, Medicine, Cancer, Internal medicine, Oncology
References
- Phase II study of Taxol in patients with advanced gastric carcinoma.
- [Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group].
- Uracil-tegafur in gastric carcinoma: a comprehensive review.
- Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group.
- Modified therapy with 5‐fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer
- One-sample multiple testing procedure for phase II clinical trials.
- Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer.
- Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.
- Cancer of the stomach. A patient care study by the American College of Surgeons.
- Progress in gastric cancer surgery in Japan and its limits of radicality
- Current status of chemotherapy for gastric cancer.
- A review of chemotherapy in gastric cancer
- 5-Fluorouracil vs. epirubicin vs. 5-fluorouracil plus epirubicin in advanced gastric carcinoma
- Rising incidence of adenocarcinoma of the esophagus and gastric cardia.
- Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.
- Extended lymph-node dissection for gastric cancer.
- Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
- Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
- Current status of chemotherapy for advanced pancreatic and gastric cancer.
- A Confidence Interval for the Median Survival Time
Cited by
- Bi-weekly chemotherapy with cisplatin, epirubicin, folinic acid and 5-fluororacil continuous infusion plus g-csf in advanced gastric cancer: a multicentric phase II study
- Targeted Therapies for Gastric Cancer
- Irinotecan, Fluorouracil and Folinic ACID (FOLFIRI) as Effective Treatment Combination for Patients with Advanced Gastric Cancer in Poor Clinical Condition
- Longitudinal quality of life study in patients with metastatic gastric cancer. Analysis modalities and clinical applicability of QoL in randomized phase II trial in a digestive oncology.
- Second-line chemotherapy with irinotecan, 5-fluorouracil and leucovorin (FOLFIRI) in relapsed or metastatic gastric cancer: lessons from clinical practice.
- A general review of the role of irinotecan (CPT11) in the treatment of gastric cancer
- Irinotecan plus cisplatin combination against metastatic gastric cancer
- Topoisomerase I inhibitors in the treatment of gastrointestinal cancer: from intravenous to oral administration.
- A Phase II Study of a Combined Biweekly Irinotecan and Monthly Cisplatin Treatment for Metastatic or Recurrent Gastric Cancer
- Dose-Finding Phase I Clinical and Pharmacokinetic Study of Orally Administered Irinotecan in Patients with Advanced Solid Tumors
- Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatment.
- Evaluation of efficacy and safety of FOLFIRI for elderly patients with gastric cancer: a first-line phase II study.
- A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma
- What have we learned and where are we going in the treatment of colorectal and gastric cancer
- A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma
- Recent developments in the clinical activity of topoisomerase-1 inhibitors.
- Current questions for the treatment of advanced gastric cancer.
- Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer
- Recent Developments in Chemotherapy of Advanced Gastric Cancer
- Phase II trial of PN401, 5-FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach: A Southwest Oncology Group study
Related papers
- UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan.
- Comprehensive genetic definition of susceptibility to toxic side effects of irinotecan in mice.
- Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients.
- Irinotecan and UFT/leucovorin in patients with advanced cancers.
- Severe irinotecan-induced toxicity in a patient with UGT1A1 28 and UGT1A1 6 polymorphisms.
- Irinotecan in small cell lung cancer
- Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer
- Pharmacogenetics and irinotecan therapy.
- Setting a new standard--irinotecan (Campto) in the second-line therapy of colorectal cancer: final results of two phase III studies and implications for clinical practice.